Why Your Funder's Financial Health Matters

Choosing a capital partner for multi-year case portfolios is a long-term institutional commitment. Here is the due diligence framework law firms should apply before signing.

Pre-settlement funding and litigation finance are long-horizon products. A case that enters funding today may not resolve for two, three, or four years. During that entire period, your funder is a counterparty to your matter — obligated to hold the advance, process payoffs, and in portfolio structures, fund ongoing draws. The financial health of the organization behind that obligation matters in ways a signing-day term sheet cannot capture.

The most important question to answer before signing with any capital provider is straightforward: will this organization still be operational, solvent, and focused on your portfolio when your case resolves? For private, independently capitalized funders, the answer is verifiable through track record and references. For funders that are publicly traded, in the process of a SPAC merger, or mid-acquisition, the answer is materially less certain. Publicly filed financial statements are the starting point: going-concern qualifications, debt covenant disclosures, and notes on pending transactions are direct signals of financial stress or organizational uncertainty.

SPAC transactions introduce a specific category of counterparty risk. A company in the middle of a SPAC merger is in organizational transition — management attention divided between deal mechanics and operations, capital potentially committed to transaction costs, and deal completion uncertain until the shareholder vote closes. For a law firm relying on that capital partner for a multi-year portfolio, a failed or delayed SPAC creates real operational risk: funding commitments may be impaired, key personnel may depart, and the combined entity may reprioritize capital deployment in ways that affect existing portfolio agreements. None of this is disclosed in the original term sheet.

Capital adequacy is a separate question from solvency. A funder can be technically solvent but operationally constrained — thin capital relative to deployment commitments, dependent on revolving credit facilities that may be repriced or called in a downcycle, or managing a portfolio with higher-than-disclosed loss rates. Ask directly about capital structure: what is the source of deployment capital, is it committed or market-dependent, and has the organization maintained consistent deployment through prior market dislocations? Funders that have operated continuously through 2020, 2022, and 2023 have a verifiable track record. Those that have not are asking you to accept untested counterparty exposure.

The practical due diligence steps are not complicated. For any funder that is publicly traded or has made SEC filings, search EDGAR for the company's most recent investor presentation, annual filing, or merger proxy. Read the risk factor disclosures and any going-concern footnotes in the financial statements. For private funders, request audited financials and ask for references from law firms with existing portfolio relationships. Ask specifically: how long has the organization been operational, who are the principals who will manage your relationship through the portfolio term, and what corporate transactions — if any — are currently pending? The answers will tell you far more than the term sheet.

Need help with a pre-settlement funding request?